- Home
- RYTM vs SKT Comparison
RYTM vs SKT Comparison
Compare RYTM & SKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- SKT
- Stock Information
- Founded
- RYTM 2008
- SKT 1981
- Country
- RYTM United States
- SKT United States
- Employees
- RYTM N/A
- SKT N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- SKT Real Estate Investment Trusts
- Sector
- RYTM Health Care
- SKT Real Estate
- Exchange
- RYTM Nasdaq
- SKT Nasdaq
- Market Cap
- RYTM 3.5B
- SKT 3.8B
- IPO Year
- RYTM 2017
- SKT 1993
- Fundamental
- Price
- RYTM $56.07
- SKT $35.82
- Analyst Decision
- RYTM Strong Buy
- SKT Buy
- Analyst Count
- RYTM 10
- SKT 9
- Target Price
- RYTM $66.90
- SKT $35.11
- AVG Volume (30 Days)
- RYTM 380.5K
- SKT 722.0K
- Earning Date
- RYTM 02-26-2025
- SKT 02-19-2025
- Dividend Yield
- RYTM N/A
- SKT 3.06%
- EPS Growth
- RYTM N/A
- SKT N/A
- EPS
- RYTM N/A
- SKT 0.88
- Revenue
- RYTM $112,530,000.00
- SKT $537,352,000.00
- Revenue This Year
- RYTM $66.58
- SKT N/A
- Revenue Next Year
- RYTM $44.63
- SKT $3.99
- P/E Ratio
- RYTM N/A
- SKT $40.82
- Revenue Growth
- RYTM 81.55
- SKT 13.69
- 52 Week Low
- RYTM $35.17
- SKT $25.94
- 52 Week High
- RYTM $68.58
- SKT $37.57
- Technical
- Relative Strength Index (RSI)
- RYTM 42.18
- SKT 66.01
- Support Level
- RYTM $56.03
- SKT $34.17
- Resistance Level
- RYTM $58.65
- SKT $36.76
- Average True Range (ATR)
- RYTM 1.87
- SKT 0.85
- MACD
- RYTM -0.27
- SKT 0.30
- Stochastic Oscillator
- RYTM 5.45
- SKT 78.49
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About SKT Tanger Inc.
Tanger Inc is a leading owner and operator of outlet and open-air retail shopping destinations. Tanger's portfolio of 38 outlet centers and one open-air lifestyle center comprises over 15 million square feet well positioned across tourist destinations and vibrant markets in U.S. states and Canada.